Cardiovascular disease and COVID-19

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 14, Issue 3, 2020, Pages 247-250

  Bansal, Manish ^a  

^a MEDANTA THE MEDICITY   (India)

Author keywords

Arrhythmia; Cardiac troponins; Cardiogenic shock; Coronavirus disease 2019; COVID 19; Heart failure; Myocardial infarction; Myocarditis; SARS CoV 2

Indexed keywords

ANTIVIRUS AGENT; TROPONIN;

ANTIVIRAL THERAPY; ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL OUTCOME; COMORBIDITY; CORONARY ARTERY THROMBOSIS; CORONAVIRUS DISEASE 2019; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART INJURY; HEART MUSCLE INJURY; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; PANDEMIC; VIRUS PNEUMONIA;

BETACORONAVIRUS; CARDIOVASCULAR DISEASES; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85082809006     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2020.03.013     Document Type: Article

References (20)

1. Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease Control and prevention. J Am Med Assoc, 2020.
2. The world health organization coronavirus disease 2019 (COVID-19) situation report –61. Available at:- https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200321-sitrep-61-covid-19.pdf?sfvrsn=f201f85c_2. (Accessed 22 March 2020)
3. Xiong, T.Y., Redwood, S., Prendergast, B., Chen, M., Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J, 2020.
4. Li, B., Yang, J., Zhao, F., et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020.
5. Zhou, F., Yu, T., Du, R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020.
6. Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
7. Chen, D., Li, X., song, q, Hu, C., Su, F., Dai, J., Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). medRxiv, 2020, 10.1101/2020.02.27.20028530.
8. Wang, D., Hu, B., Hu, C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc, 2020.
9. Arentz, M., Yim, E., Klaff, L., et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state. J Am Med Assoc, 2020.
10. Lippi, G., Plebani, M., Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med, 2020.
11. Oudit, G.Y., Kassiri, Z., Jiang, C., et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 39 (2009), 618–625.
12. Wu, Q., Zhou, L., Sun, X., et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep, 7, 2017, 9110.
13. Corrales-Medina, V.F., Alvarez, K.N., Weissfeld, L.A., et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. J Am Med Assoc 313 (2015), 264–274.
14. Tam, C.F., Cheung, K.S., Lam, S., et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes, 2020 CIRCOUTCOMES120006631.
15. ACC clinical bulletin focuses on cardiac implications of coronavirus (COVID-19). Available at:- https://www.acc.org/latest-in-cardiology/articles/2020/02/13/12/42/acc-clinical-bulletin-focuses-on-cardiac-implications-of-coronavirus-2019-ncov. (Accessed 22 March 2020)
16. ASE statement on COVID-19. Available at:- https://www.asecho.org/ase-statement-covid-19/. (Accessed 22 March 2020)
17. Ferrario, C.M., Jessup, J., Chappell, M.C., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111 (2005), 2605–2610.
18. HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. Available at:- https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. (Accessed 22 March 2020)
19. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. Available at:- https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. (Accessed 22 March 2020)
20. Information for clinicians on therapeutic options for COVID-19 patients. Available at:- https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html. (Accessed 22 March 2020)